Efficacy of Biosimilar Infliximab-Dyyb in Non-Infectious Uveitis-Reference-Cited by-同舟云学术

Efficacy of Biosimilar Infliximab-Dyyb in Non-Infectious Uveitis

Published:2023-08-15 Issue: Volume: Page:1-5
ISSN:0927-3948
Container-title:Ocular Immunology and Inflammation
language:en
Short-container-title:Ocular Immunology and Inflammation

Author:

Zaguia Fatma¹,Randerson Edward L.¹,Moorthy Ramana S.²,Goldstein Debra A.¹

Affiliation:

1. Uveitis Service, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA

2. Uveitis Service, Indiana University School of Medicine, Indianapolis, Indiana, USA

Funder

AbbVie Pharmaceuticals

Publisher

Informa UK Limited

Subject

Ophthalmology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/09273948.2023.2244071

Reference15 articles.

1. Expert Panel Recommendations for the Use of Anti–Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders

2. Anti–tumor necrosis factor-α therapy in uveitis

3. A Prospective Trial of Infliximab Therapy for Refractory Uveitis

4. Infliximab in the treatment of refractory posterior uveitis

5. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Scientific considerations in demonstrating biosimilarity to a reference product. 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry;Ophthalmology and Therapy;2024-01-11